• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

UCR Scientists Pave the Way for Diabetes and Cancer Patients to Forget Injections

Share:

November 14, 2022

Researchers at UC Riverside are paving the way for diabetes and cancer patients to forget needles and injections, and instead take pills to manage their conditions.

Some drugs for these diseases dissolve in water, so transporting them through the intestines, which receive what we drink and eat, is not feasible. As a result, these drugs cannot be administered by mouth. However, UCR scientists have created a chemical “tag” that can be added to these drugs, allowing them to enter blood circulation via the intestines.

The details of how they found the tag, and demonstrations of its effectiveness, are described in a new Journal of the American Chemical Society paper.

The tag is composed of a small peptide, which is like a protein fragment. “Because they are relatively small molecules, you can chemically attach them to drugs, or other molecules of interest, and use them to deliver those drugs orally,” said Min Xue, UCR chemistry professor who led the research.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Xue’s laboratory was testing something unrelated when the researchers observed these peptides making their way into cells.

This observation was unexpected, Xue said, because previously, the researchers believed that this type of delivery tag needed to carry positive charges to be accepted into the negatively charged cells. Their work with this neutral peptide tag, called EPP6, shows that belief was not accurate.

Testing the peptide’s ability to move through a body, the Xue group teamed up with Kai Chen’s group in the Keck School of Medicine at the University of Southern California and fed the peptide to mice. Using a PET scan -; a technique similar to a whole-body X-ray that is available at USC, the team observed the peptide accumulating in the intestines, and documented its ultimate transfer into the animals’ organs via the blood.

Having proven the tag successfully navigated the circulatory systems through oral administration, the team now plans to demonstrate that the tag can do the same thing when attached to a selection of drugs. “Quite compelling preliminary results make us think we can push this further,” Xue said.

Many drugs, including insulin, must be injected. The researchers are hopeful their next set of experiments will change that, allowing them to add this tag to a wide variety of drugs and chemicals, changing the way those molecules move through the body.

“This discovery could lift a burden on people who are already burdened with illness,” Xue said.
Source: News Medical

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Scanwell Health Announces Nationwide Launch of Smartphone-Enabled Test and Treatment Service for Urinary Tract Infections via Partnership with Lemonaid HealthScanwell Health Announces Nationwide Launch of Smartphone-Enabled Test and Treatment Service for Urinary Tract Infections via Partnership with Lemonaid Health
  • Agfa to Consider Selling Hospital IT and Integrated Care BusinessAgfa to Consider Selling Hospital IT and Integrated Care Business
  • Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial ResultsTheriva Biologics to Reschedule Conference Call and Webcast to Discuss Third Quarter 2022 Operational Highlights and Financial Results
  • Versum Materials Announces CFIUS Clearance of Merger with Merck KGaA, Darmstadt, GermanyVersum Materials Announces CFIUS Clearance of Merger with Merck KGaA, Darmstadt, Germany
  • CareSource, Healthify Partner to Address Social Determinants of Health in OhioCareSource, Healthify Partner to Address Social Determinants of Health in Ohio
  • Cytocom and Cleveland BioLabs Announce Definitive Merger AgreementCytocom and Cleveland BioLabs Announce Definitive Merger Agreement
  • COVID-19 Underscores Need for Identity Governance AdministrationCOVID-19 Underscores Need for Identity Governance Administration
  • Flexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative PainFlexion Therapeutics and Xenon Pharmaceuticals Announce Flexion’s Acquisition of an Investigational NaV1.7 Inhibitor for the Treatment of Post-Operative Pain

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications